WO2023142881A1 - Procédé de construction d'une souche produisant de la thréonine - Google Patents
Procédé de construction d'une souche produisant de la thréonine Download PDFInfo
- Publication number
- WO2023142881A1 WO2023142881A1 PCT/CN2022/143762 CN2022143762W WO2023142881A1 WO 2023142881 A1 WO2023142881 A1 WO 2023142881A1 CN 2022143762 W CN2022143762 W CN 2022143762W WO 2023142881 A1 WO2023142881 A1 WO 2023142881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dehydrogenase
- enhanced
- threonine
- pyruvate
- activity
- Prior art date
Links
- 239000004473 Threonine Substances 0.000 title claims abstract description 74
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 30
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims abstract description 106
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims abstract description 52
- 108010064711 Homoserine dehydrogenase Proteins 0.000 claims abstract description 49
- 230000014509 gene expression Effects 0.000 claims abstract description 32
- 108010055400 Aspartate kinase Proteins 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 230000037361 pathway Effects 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 claims abstract description 15
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 claims abstract description 15
- 108010071598 homoserine kinase Proteins 0.000 claims abstract description 15
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 13
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 13
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 13
- 102000006843 Threonine synthase Human genes 0.000 claims abstract description 13
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 241000186216 Corynebacterium Species 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 101710088194 Dehydrogenase Proteins 0.000 claims description 51
- 244000005700 microbiome Species 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 37
- 102000004190 Enzymes Human genes 0.000 claims description 34
- 108090000790 Enzymes Proteins 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 28
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 27
- 210000000349 chromosome Anatomy 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 8
- 102000001253 Protein Kinase Human genes 0.000 claims description 6
- 230000003313 weakening effect Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 241000186031 Corynebacteriaceae Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 64
- 229960002898 threonine Drugs 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 25
- 238000012408 PCR amplification Methods 0.000 description 23
- 238000010276 construction Methods 0.000 description 19
- 101150049887 cspB gene Proteins 0.000 description 18
- 101150041068 cspJ gene Proteins 0.000 description 18
- 101150010904 cspLB gene Proteins 0.000 description 18
- 229930006000 Sucrose Natural products 0.000 description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000005720 sucrose Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101100462488 Phlebiopsis gigantea p2ox gene Proteins 0.000 description 6
- 101150063051 hom gene Proteins 0.000 description 6
- 101150035025 lysC gene Proteins 0.000 description 6
- 101150060030 poxB gene Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 101150000850 thrC gene Proteins 0.000 description 4
- 238000011426 transformation method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000002074 deregulated effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 101100001356 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) lysC gene Proteins 0.000 description 2
- 101100020115 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) thrB gene Proteins 0.000 description 2
- 101100046155 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) thrC gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- -1 NCBI number: Cg1337 Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 101150097303 glyA gene Proteins 0.000 description 2
- 101150079604 glyA1 gene Proteins 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 101150072448 thrB gene Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- VUUZLZXGRRDWBP-AAZKHNGSSA-N (2s,3r)-2-azanyl-3-oxidanyl-butanoic acid Chemical compound C[C@@H](O)[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O VUUZLZXGRRDWBP-AAZKHNGSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100436101 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) Cgl0240 gene Proteins 0.000 description 1
- 101100387228 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) asd gene Proteins 0.000 description 1
- 101100387272 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) hom gene Proteins 0.000 description 1
- 101100337176 Escherichia coli (strain K12) gltB gene Proteins 0.000 description 1
- 101100505027 Escherichia coli (strain K12) gltD gene Proteins 0.000 description 1
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101100057034 Talaromyces wortmannii astB gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150070145 aspB gene Proteins 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 229940085300 biotin 5 mg Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 101150100742 dapL gene Proteins 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01003—Homoserine dehydrogenase (1.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/05—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a quinone or similar compound as acceptor (1.2.5)
- C12Y102/05001—Pyruvate dehydrogenase (quinone) (1.2.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01021—D-Amino-acid transaminase (2.6.1.21), i.e. D-alanine aminotransferase/transaminase or D-aspartic aminotransferase/transaminase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/02—Phosphotransferases with a carboxy group as acceptor (2.7.2)
- C12Y207/02004—Aspartate kinase (2.7.2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/03—Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)
- C12Y402/03001—Threonine synthase (4.2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Definitions
- the invention belongs to the technical field of microbial engineering, and in particular relates to a method for constructing a threonine-producing bacterial strain.
- threonine from oxaloacetate requires five steps of catalytic reactions, which are aspartate kinase (encoded by lysC), aspartate semialdehyde dehydrogenase (encoded by asd), and homoserine dehydrogenase (encoded by asd). Hydrogenase (hom coded), homoserine kinase (thrB) and threonine synthase (thrC) coded.
- Corynebacterium glutamicum hom gene coding for a feedback-resistant homoserine dehydrogenase.[J].Journal of Bacteriology,1991,173(10):3228-3230), lysC gene (Eikmanns B J,Eggeling L,Sahm H.Molecular aspects of lysine,threonine,and isoleucine biosynthesis in Corynebacterium glutamicum.[J].Antonie Van Leeuwenhoek,1993,64(2):145-163).
- the purpose of the present invention is to improve the ability of the strain to produce threonine by inactivating pyruvate quinone dehydrogenase, thereby providing a method for constructing a threonine (L-threonine) producing strain.
- the present invention provides a modified microorganism of the genus Corynebacterium, which has a reduced or lost activity of pyruvate quinone dehydrogenase compared with an unmodified microorganism, and the microorganism Enhanced threonine production capacity compared to unmodified microorganisms.
- the reference sequence number of pyruvate quinone dehydrogenase on NCBI is WP_011015247.1, or an amino acid sequence with 90% similarity thereto.
- the reduction or loss of the activity of pyruvate quinone dehydrogenase in the microorganism is achieved by reducing the expression of the gene encoding pyruvate quinone dehydrogenase or knocking out the endogenous gene encoding pyruvate quinone dehydrogenase.
- the microorganism is any one of the following 1 ⁇ 5:
- the enhancement of the activity of enzymes related to the threonine synthesis pathway in the microorganism is achieved by being selected from the following 1) to 6), or an optional combination:
- the Corynebacterium glutamicum described in the present invention is Corynebacterium glutamicum (Corynebacterium glutamicum), and Corynebacterium glutamicum includes ATCC13032, ATCC13870, ATCC13869, ATCC21799, ATCC21831, ATCC14067, ATCC13287 etc. (see NCBI Corunebacterium glutamicum evolutionary tree https:/ /www.ncbi.nlm.nih.gov/genome/469), more preferably Corynebacterium glutamicum ATCC 13032.
- the present invention provides a method for constructing a threonine-producing strain, the method comprising:
- the enhanced approach is selected from the following 1) to 5), or an optional combination:
- the present invention provides a method for producing threonine, the method comprising the steps of:
- step b) collecting the threonine produced from said culture obtained in step a).
- the present invention provides the application of knockout or reduced expression of gene encoding pyruvate quinone dehydrogenase in threonine fermentation production or improvement of threonine fermentation yield.
- the fermentation yield of threonine is improved by inactivating pyruvate quinone dehydrogenase in Corynebacterium having amino acid production ability.
- the Corynebacterium glutamicum described in the present invention is Corynebacterium glutamicum (Corynebacterium glutamicum), and Corynebacterium glutamicum includes ATCC13032, ATCC13870, ATCC13869, ATCC21799, ATCC21831, ATCC14067, ATCC13287 etc. (see NCBI Corunebacterium glutamicum evolutionary tree https:/ /www.ncbi.nlm.nih.gov/genome/469), more preferably Corynebacterium glutamicum ATCC 13032.
- the present invention provides the use of the modified Corynebacterium genus microorganism or the threonine-producing strain constructed according to the above-mentioned method in the fermentative production of threonine or in improving the fermentative yield of threonine.
- transformation methods of the above-mentioned related strains are transformation methods known to those skilled in the art.
- the present invention has at least the following advantages and beneficial effects:
- the present invention focuses on the influence of the inactivation of pyruvate quinone dehydrogenase on the production of threonine, and inactivates the coding gene of pyruvate quinone dehydrogenase on the basis of the Corynebacterium glutamicum ATCC 13032 strain to obtain bacterial strain SMCT322, Threonine
- the amino acid content is 0.2g/L. It can be seen that the loss of pyruvate quinone dehydrogenase activity is beneficial to the production of threonine.
- the threonine synthesis pathway of the strain was further strengthened, mainly including aspartokinase, homoserine dehydrogenase, The expression of at least one of aspartate semialdehyde dehydrogenase, aspartate aminotransferase, homoserine kinase, and threonine synthase is enhanced or deregulated.
- Inactivation or weakening during the transformation process includes promoter replacement, ribosome binding site changes, point mutations, and sequence deletions.
- Expression enhancement during the transformation process includes promoter replacement and ribosome binding site changes. , copy number increase, plasmid overexpression and other means, and the above means are well known to researchers in the field. The above means cannot be exhausted by examples, and the specific examples only use promoter enhancement as a representative for illustration.
- the present invention adopts following technical scheme:
- One of the technical schemes of the present invention provides a method for producing threonine by using a strain that loses activity of pyruvate quinone dehydrogenase.
- the second technical solution of the present invention provides a method for inactivating pyruvate quinone dehydrogenase and aspartokinase, homoserine dehydrogenase, aspartate semialdehyde dehydrogenase, homoserine kinase, threonine Synthase at least one expression-enhanced or deregulated expression-enhanced strain to produce threonine.
- the third technical solution of the present invention is to provide a method for producing threonine using a bacterial strain in which pyruvate quinone dehydrogenase is inactivated and the expression of aspartokinase and homoserine dehydrogenase is enhanced.
- the fourth technical solution of the present invention is to provide a method for producing threonine using strains with inactivated pyruvate quinone dehydrogenase and enhanced expression of aspartate kinase, homoserine dehydrogenase, and aspartate aminotransferase .
- the seventh technical solution of the present invention is to provide a method for producing threonine using a bacterial strain in which the pyruvate quinone dehydrogenase is inactivated and the expression of aspartokinase, homoserine dehydrogenase, and threonine synthase is enhanced.
- Aspartokinase encoding gene name lysC, NCBI number: cg0306, Cgl0251, NCgl0247.
- Aspartate semialdehyde dehydrogenase encoding gene name asd, NCBI number: Cgl0252, Cg0307, NCgl0248.
- Homoserine dehydrogenase encoding gene name hom, NCBI number: Cg1337, Cgl1183, NCgl1136.
- Threonine synthase encoding gene name thrC, NCBI number: cg2437, Cgl2220, NCgl2139.
- Homoserine kinase encoding gene thrB, NCBI number: cg1338, Cgl1184, NCgl1137.
- Aspartate aminotransferase encoding gene aspB, NCBI number: cg0294, Cgl0240, NCgl0237.
- the PCR amplification system is as follows:
- the PCR amplification procedure is as follows:
- Transformation method refer to the instructions of Trans1-T1 Phage Resistant Chemically Competent Cell.
- the upstream homology arm up was obtained by PCR amplification with the P21/P22 primer pair
- the promoter fragment Psod was obtained by PCR amplification with the P23/P24 primer pair
- the P25/P26 primer lysCg1a-T311I was obtained by PCR amplification
- the downstream homology arm dn was obtained by PCR amplification with the P27/P28 primer pair. Fusion PCR was carried out with P21/P24 primer pair and up and Psod as templates to obtain the fragment up-Psod.
- the full-length fragment up-Psod-lysCg1a-T311I-dn was obtained by fusion PCR with P21/P28 primer pair and up-Psod, lysCg1a-T311I, dn as templates.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, and Trans1T1 competent cells were transformed to obtain the recombinant plasmid pK18mobsacB-P sod -lysC g1a-T311I .
- g1a means that the first base of the start codon of the lysC gene (see SEQ ID NO: 1 for the wild-type gene sequence of lysC) is mutated from g to a
- T311I means that the 311th base of the aspartokinase encoded by the lysC gene is The amino acid is mutated from T to I.
- PCR amplification was performed with the P29/P30 primer pair to obtain the upstream homology arm up, and the ATCC14067 genome was used as a template to perform PCR amplification with the P31/P32 primer pair to obtain the promoter fragment PcspB
- the ATCC13032 genome was used as a template to obtain hom G378E by PCR amplification with P33/P34 primer pair, and the downstream homology arm dn was obtained by PCR amplification with P35/P36 primer pair.
- the fragment up-PcspB was obtained.
- the full-length fragment up-PcspB-hom G378E -dn was obtained by fusion PCR with P29/P36 primer pair and up-PcspB, hom G378E , dn as template.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, and Trans1T1 competent cells were transformed to obtain the recombinant plasmid pK18mobsacB-P cspB -hom G378E .
- the upstream homology arm up was obtained by PCR amplification with the P1/P2 primer pair
- the promoter fragment Psod was obtained by PCR amplification with the P3/P4 primer pair
- the P5/P6 primer Perform PCR amplification to obtain the downstream homology arm dn.
- the full-length fragment up-Psod-dn was obtained by fusion PCR with P1/P6 primer pair and up, Psod, dn as templates.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, transformed into Trans1T1 competent cells, and obtained the recombinant plasmid pK18mobsacB-P sod -asd.
- the upstream homology arm up was obtained by PCR amplification with the P103/P104 primer pair
- the promoter fragment Psod was obtained by PCR amplification with the P105/P106 primer pair
- the P107/P108 primer Perform PCR amplification to obtain the downstream homology arm dn.
- the full-length fragment up-Psod-dn was obtained by fusion PCR with P103/P108 primer pair and up, Psod, dn as templates.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, and Trans1T1 competent cells were transformed to obtain the recombinant plasmid pK18mobsacB-P sod -aspB.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, and Trans1T1 competent cells were transformed to obtain the recombinant plasmid pK18-P cspB -thrB.
- the upstream homology arm up was obtained by PCR amplification with the P37/P38 primer pair, and the promoter fragment Psod-thrC g1a was obtained by PCR amplification with the P39/P40 primer pair.
- the dn of the downstream homology arm was obtained by PCR amplification with the /P42 primer pair.
- the full-length fragment up-Psod-thrC g1a -dn was obtained by fusion PCR with P37/P42 primer pair and up, Psod-thrC g1a , dn as templates.
- pK18mobsacB was digested with BamHI/HindIII. The two were assembled with a seamless cloning kit, and Trans1T1 competent cells were transformed to obtain the recombinant plasmid pK18mobsacB-P sod -thrC g1a .
- g1a means that the first base of the start codon of the thrC gene (see SEQ ID NO: 2 for the wild-type gene sequence of thrC) is mutated from g to a.
- the primers used in the construction process are shown in Table 1:
- ATCC13032 competent cells were prepared according to the classical glutamicum method (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18mobsacB- ⁇ poxB was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15mg/L kanamycin, wherein the gene of interest was inserted into the chromosome due to homology.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm. During this culture, the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT322.
- ATCC13032 competent cells were prepared according to the classical glutamicum method (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18mobsacB-Psod-lysC g1a-T311I was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15 mg/L kanamycin, wherein the gene of interest was inserted due to homology into the chromosome.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm.
- the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT323.
- SMCT323 competent cells were prepared according to the classical glutamicum method (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18mobsacB-P cspB -hom G378E was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15mg/L kanamycin, wherein the gene of interest was inserted into the in the chromosome.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm. During this culture, the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT324.
- SMCT324 competent cells were prepared according to the classical method of glutamicum (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18mobsacB-P sod -asd was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15mg/L kanamycin, in which the gene of interest was inserted into the chromosome due to homology middle.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm. During this culture, the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT325.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT326.
- SMCT324 competent cells were prepared according to the classical method of glutamicum (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18-P cspB -thrB was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15 mg/L kanamycin, in which the gene of interest was inserted into the chromosome due to homology middle.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm. During this culture, the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT327.
- SMCT324 competent cells were prepared according to the classical method of glutamicum (C. glutamicum Handbook, Chapter 23).
- the recombinant plasmid pK18mobsacB-P sod -thrC g1a was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15mg/L kanamycin, wherein the gene of interest was inserted into the in the chromosome.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm. During this culture, the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strain was obtained and named SMCT328.
- SMCT324, SMCT325, SMCT326, SMCT327, SMCT328 competent cells were prepared according to the classical method of glutamicum (C. glutamicum Handbook, Charpter 23).
- the recombinant plasmid pK18mobsacB- ⁇ poxB was used to transform the competent cells by electroporation, and the transformants were selected on the selection medium containing 15mg/L kanamycin, in which the gene of interest was inserted into the chromosome due to homology.
- the screened transformants were cultured overnight in common liquid brain-heart infusion medium at a temperature of 30° C. on a rotary shaker at 220 rpm.
- the transformants undergo a second recombination, whereby the vector sequence is removed from the genome by gene exchange.
- the culture was serially diluted (from 10 -2 to 10 -4 ), the diluted solution was spread on common solid brain heart infusion medium containing 10% sucrose, and cultured at 33°C for 48 hours. Strains grown on sucrose media do not carry the inserted vector sequence in their genome.
- the target sequence was amplified by PCR and analyzed by nucleotide sequencing, and the target mutant strains were named SMCT329, SMCT330, SMCT331, SMCT332, SMCT333.
- the strains obtained are shown in Table 2:
- Embodiment 3 constructs bacterial strain shaking flask verification
- Seed activation medium BHI 3.7%, agar 2%, pH7.
- Seed medium peptone 5/L, yeast extract 5g/L, sodium chloride 10g/L, ammonium sulfate 16g/L, urea 8g/L, potassium dihydrogen phosphate 10.4g/L, dipotassium hydrogen phosphate 21.4g /L, biotin 5mg/L, magnesium sulfate 3g/L. Glucose 50g/L, pH 7.2.
- Fermentation medium corn steep liquor 50mL/L, glucose 30g/L, ammonium sulfate 4g/L, MOPS 30g/L, potassium dihydrogen phosphate 10g/L, urea 20g/L, biotin 10mg/L, magnesium sulfate 6g/L , ferrous sulfate 1g/L, VB1 ⁇ HCl 40mg/L, calcium pantothenate 50mg/L, nicotinamide 40mg/L, manganese sulfate 1g/L, zinc sulfate 20mg/L, copper sulfate 20mg/L, pH 7.2.
- Seed training picking SMCT181, SMCT182, SMCT183, SMCT184, SMCT185, SMCT186, SMCT187, SMCT188, SMCT189, SMCT190, SMCT192, SMCT193, SMCT194, SMCT193, SMCT194, SMCT194, SMCT194, SMCT194 , SMCT195, SMCT196 and SMCT197
- Fermentation culture inoculate 2 mL of seed solution into a 500 mL Erlenmeyer flask containing 20 mL of fermentation medium, and culture at 33° C. and 220 r/min for 24 hours with shaking.
- the threonine yields of different pyruvate quinone dehydrogenase inactivated strains were different, ranging from 0.2g/L to 1.2g/L, indicating that the inactivation of pyruvate quinone dehydrogenase was related to the Combinations have different effects, and when combined with aspartate kinase, homoserine dehydrogenase, aspartate semialdehyde dehydrogenase, aspartate aminotransferase, homoserine kinase in the threonine synthesis pathway When combining at least one expression enhancement of threonine synthase and threonine synthase, the threonine production can be increased by 10-21 times.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention porte sur un procédé de construction d'une souche productrice de thréonine. Dans la présente invention, l'utilisation d'une souche (Corynebacterium) inactivée par la pyruvate quinone déshydrogénase dans la production de thréonine peut augmenter le rendement en thréonine jusqu'à 25 à 45,8 % par comparaison avec l'utilisation d'une souche non modifiée. En combinant en outre la souche inactivée par la pyruvate quinone déshydrogénase avec l'expression améliorée d'au moins l'une parmi l'aspartokinase, l'homosérine déshydrogénase, l'aspartate semi-aldéhyde déshydrogénase, l'aspartate aminotransférase, l'homosérine kinase, la thréonine synthase, etc, dans une voie de synthèse de thréonine, le rendement en thréonine est augmenté de 10 à 21 fois. La procédé présente une nouvelle approche pour la production à grande échelle de thréonine et présente une grande valeur d'application.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210112879.3 | 2022-01-29 | ||
CN202210112879.3A CN116555134A (zh) | 2022-01-29 | 2022-01-29 | 产苏氨酸菌株的构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023142881A1 true WO2023142881A1 (fr) | 2023-08-03 |
Family
ID=87470505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/143762 WO2023142881A1 (fr) | 2022-01-29 | 2022-12-30 | Procédé de construction d'une souche produisant de la thréonine |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116555134A (fr) |
WO (1) | WO2023142881A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1767616A2 (fr) * | 2005-09-22 | 2007-03-28 | Degussa GmbH | Procédé de préparation de L-acides aminés ou de cétoacides en utilisant des bactéries coryneformes ayant une expression attenuée du gène aceE (pdhA) |
US20100184162A1 (en) * | 2006-02-02 | 2010-07-22 | Akira Imaizumi | Method for production of an l-amino acid |
CN113322218A (zh) * | 2020-02-28 | 2021-08-31 | 廊坊梅花生物技术开发有限公司 | 重组谷氨酸棒杆菌及生产l-苏氨酸的方法 |
-
2022
- 2022-01-29 CN CN202210112879.3A patent/CN116555134A/zh active Pending
- 2022-12-30 WO PCT/CN2022/143762 patent/WO2023142881A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1767616A2 (fr) * | 2005-09-22 | 2007-03-28 | Degussa GmbH | Procédé de préparation de L-acides aminés ou de cétoacides en utilisant des bactéries coryneformes ayant une expression attenuée du gène aceE (pdhA) |
US20100184162A1 (en) * | 2006-02-02 | 2010-07-22 | Akira Imaizumi | Method for production of an l-amino acid |
CN113322218A (zh) * | 2020-02-28 | 2021-08-31 | 廊坊梅花生物技术开发有限公司 | 重组谷氨酸棒杆菌及生产l-苏氨酸的方法 |
Non-Patent Citations (2)
Title |
---|
BLOMBACH BASTIAN; SCHREINER MARK E.; MOCH MATTHIAS; OLDIGES MARCO; EIKMANNS BERNHARD J.: "Effect of pyruvate dehydrogenase complex deficiency on-lysine production with", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 76, no. 3, 2 March 2007 (2007-03-02), Berlin/Heidelberg, pages 615 - 623, XP037048381, ISSN: 0175-7598, DOI: 10.1007/s00253-007-0904-1 * |
MA, HONGWU; LIU, HUIJUAN; ZHU, NIANQING; CHEN, TAO: "Metabolic Engineering of Corynebacterium glutamicum for Acetoin Production", JOURNAL OF TIANJIN UNIVERSITY (SCIENCE AND TECHNOLOGY), vol. 47, no. 11, 30 November 2014 (2014-11-30), CN , pages 967 - 972, XP009548026, ISSN: 0493-2137, DOI: 10.11784/tdxbz201304053 * |
Also Published As
Publication number | Publication date |
---|---|
CN116555134A (zh) | 2023-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6961819B2 (ja) | L−リジンを生産する組換え菌、その構築方法およびl−リジンの生産方法 | |
JP6082025B2 (ja) | L−リジン生産能を有する微生物を用いてl−リジンを生産する方法 | |
CN110699310B (zh) | 一种四氢嘧啶高产谷氨酸棒杆菌及其应用 | |
JP2001120269A (ja) | 発酵法によるl−リジンの製造法 | |
JP7350994B2 (ja) | 新規なプロモーター及びそれを用いた標的物質生産方法 | |
WO2023142881A1 (fr) | Procédé de construction d'une souche produisant de la thréonine | |
WO2023142853A1 (fr) | Procédé pour la construction d'une bactérie génétiquement modifiée pour une production élevée de thréonine | |
WO2023151412A1 (fr) | Micro-organisme corynebacterium modifié, son procédé de construction et son utilisation dans la production de thréonine | |
WO2023142861A1 (fr) | Procédé de construction d'une bactérie modifiée produisant de la thréonine | |
WO2023151408A1 (fr) | Procédé de construction pour souche avec production à haut rendement de thréonine | |
KR102377745B1 (ko) | 신규 프로모터 및 이의 용도 | |
WO2023142860A1 (fr) | Procédé de construction d'une bactérie génétiquement modifiée produisant de la thréonine | |
WO2023151421A1 (fr) | Micro-organisme corynebacterium modifié, son utilisation et son procédé de construction | |
WO2023142872A1 (fr) | Micro-organisme modifié du genre corynebacterium produisant de la thréonine, son procédé de construction et son utilisation | |
WO2023151406A1 (fr) | Procédé de construction d'une souche produisant de la thréonine | |
WO2023142848A1 (fr) | Promoteur, micro-organisme recombiné producteur de thréonine et utilisation associée | |
WO2023142873A1 (fr) | Microorganisme modifié du genre corynebacterium, son utilisation dans la production de thréonine, et son procédé de construction | |
WO2023151409A1 (fr) | Procédé de construction de bactéries modifiées à haut rendement pour la thréonine | |
WO2023142855A1 (fr) | Micro-organisme recombiné, son procédé de fabrication et son utilisation | |
WO2023142862A1 (fr) | Micro-organisme recombinant pour la production de thréonine et son utilisation | |
WO2023142871A1 (fr) | Micro-organisme modifié du genre corynebacterium, son procédé de construction et son utilisation | |
WO2023142859A1 (fr) | Micro-organisme corynebacterium modifié, son procédé de construction et son utilisation | |
WO2023151407A1 (fr) | Procédé de construction d'une souche productrice de thréonine | |
WO2023151411A1 (fr) | Micro-organisme recombiné pour la production de thréonine, son procédé de construction et son utilisation | |
WO2023142854A1 (fr) | Souche de production de thréonine et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22923666 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |